Constitutional Council invalidates levy on pharmaceutical companies
By the AFREEQUE newsroom, based on BFMTV
France’s Constitutional Council on Friday overturned the method for calculating a contribution on reimbursable medicines, whose tax base included discounts granted to the Health Insurance system. According to BFMTV, amounts paid by pharmaceutical companies between 2014 and 2024 have consequently been invalidated, following an initial challenge by the Court of Cassation in March 2025.
France’s Constitutional Council on Friday 20 November annulled the amounts paid by pharmaceutical companies under the contribution on increased sales of reimbursable medicines between 2014 and 2024. The Council invalidated the fifth section of Article 28 of the 2026 Social Security Financing Act, which had endorsed a calculation method incorporating commercial discounts granted to the Health Insurance system.
The decision follows a ruling by the Court of Cassation in March 2025. The court had considered that discounts granted on reimbursed medicines should be deducted from the turnover used as the basis for calculating this contribution, known as the safeguard clause. Around ten pharmaceutical companies, including Alexion Pharma France and AbbVie, had referred the matter to the Constitutional Council after the adoption of the legislative provision intended to confirm the previous method.
To justify its decision, the Constitutional Council considered that no sufficiently important public interest requirement justified infringing the rights of the companies concerned. The contribution was levied annually on medicine manufacturers when the growth in their sales exceeded certain thresholds.






